Allan W. Wolkoff
<p><span>Dr. Allan Wolkoff's interest in research was sparked when he worked in a biochemistry lab to help pay college bills. He began his medical studies at Dartmouth Medical College and transferred to the Albert Einstein College of Medicine where he obtained his M.D. degree. With the exception of a two year period when he was Clinical Associate in Gastroenterology-Hepatology in the Digestive Disease Branch, National Institute of Arthritis, Metabolism and Digestive Disease, he has remained at Albert Einstein. His early mentor, Irwin M. Arias, M.D. of the National Institutes of Health said of Wolkoff’s work, “He built an exemplary global reputation in hepatology research, education, training and scholarship. A major participant in the creation of the Marion Bessin Liver Research Center at Albert Einstein, Dr. Wolkoff has taken advantage of the strong, interactive basic science departments and is a leader in bridging understanding of hepatocyte biology with the pathogenesis of acquired and inheritable liver diseases.” </span></p>
<p><span>Dr. Wolkoff is a pioneer in the combining of disciplines that inform basic understanding of hepatocyte function and relation to disease and is recognized worldwide for providing new windows into physiology and pathophysiology. </span><span>He has had articles published in over 100 peer-reviewed publications, given many invited lectures and has had continuous NIH-supported research. In addition, he has served on advisory committees of several NIH-supported liver research centers. In 2006, he was presented the AASLD Distinguished Service Award. In 2012, he received the <span>highly prestigious 2012 Distinguished Scientific Achievement Award from the American Liver Foundation.</span></span></p>
Diseases of the liver and biliary tract including chronic liver disease, fatty liver disease, hepatitis, inheritable disorders of the liver, drug toxicity, and unexplained jaundice.<quillbot-extension-portal></quillbot-extension-portal>
Research interests include the mechanism by which the liver removes drugs and other compounds from the circulation and how its dysfunction may lead to drug toxicity.<quillbot-extension-portal></quillbot-extension-portal>
<p>Allan W. Wolkoff, MD, is Chief, Hepatology, Herman Lopata Chair in Liver Disease Research and Professor, Medicine and Developmental & Molecular Biology at Montefiore Einstein. His clinical focus centers on diseases of the liver and biliary tract, including chronic liver disease, fatty liver disease, hepatitis, inheritable disorders of the liver, drug toxicity and unexplained jaundice.</p><p>Dr. Wolkoff began his medical studies at Dartmouth Medical College and transferred to Einstein, where he earned his Doctor of Medicine in 1972. He completed an internship at Bronx Municipal Hospital Center in 1973 before becoming an Assistant Resident in Medicine until 1974. Following this, Dr. Wolkoff became a Clinical Associate in Gastroenterology-Hepatology at the National Institutes of Health (NIH) until 1976.</p><p>A pioneer in combining disciplines that inform basic understanding of hepatocyte function and relation to disease, Dr. Wolkoff is recognized worldwide for providing new windows into physiology and pathophysiology. His research interests include the mechanism by which the liver removes drugs and other compounds from circulation and how its dysfunction may lead to drug toxicity. He has had articles published in over 100 peer-reviewed publications, given many invited lectures and has had continuous NIH-supported research.</p><p>Dr. Wolkoff has served on advisory committees of several NIH-supported liver research centers. In 2006, he was presented with the American Association for the Study of Liver Diseases (AASLD) Distinguished Service Award. In 2012, he received the highly prestigious Distinguished Scientific Achievement Award from the American Liver Foundation. He was named Physician of the Year by the Greater New York Division of the American Liver Foundation in 2015 and won the National Leadership Award from the American Liver Foundation in 2022.</p>